Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Awareness, Care & Treatment In Obesity Management - An International Observation Among Teens (ACTION Teens)
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12987
- Registration Number
- NCT05013359
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Gatwick, United Kingdom
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 679
- Registration Number
- NCT05013229
- Locations
- 🇺🇸
Endeavor Health, Skokie, Illinois, United States
🇺🇸Andres Garcia-Zuniga, MD, P.A, Laredo, Texas, United States
🇫🇷Centre de Recherche Clinique Portes Du Sud, Venissieux, France
A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese Men
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT05003440
- Locations
- 🇯🇵
Hakata Clinic, Fukuoka, Japan
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 151
- Registration Number
- NCT04998136
- Locations
- 🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of
🇹🇭Obstetrics&Gynecology King Chulalongkorn Memorial Hospital, Bangkok, Thailand
🇹🇭Siriraj Hospital_Bangkok_1, Bangkok, Thailand
A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
- Conditions
- Interventions
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 255
- Registration Number
- NCT04992065
- Locations
- 🇺🇸
Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States
🇳🇱Deventer Ziekenhuis, Deventer, Netherlands
🇩🇪MVZ CCB Frankfurt Und Main-Taunus GbR, Frankfurt, Germany
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 92
- Registration Number
- NCT04982575
- Locations
- 🇺🇸
Macoupin Research Group, Gillespie, Illinois, United States
🇺🇸Accellacare, Wilmington, North Carolina, United States
🇺🇸Clinical Trial Research Associates,Inc, Plantation, Florida, United States
SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3400
- Registration Number
- NCT04972721
- Locations
- 🇧🇷
Master Centre for Brazil, Säo Paulo, Sao Paulo, Brazil
🇨🇦Master Centre for Canada, Mississauga, Ontario, Canada
🇧🇷Hospital do Coração do Brasil, Brasilia, Distrito Federal, Brazil
A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 110
- Registration Number
- NCT04970654
- Locations
- 🇨🇳
Hunan Children's Hospital, Changsha, Hunan, China
🇨🇳Jiangxi Provincial Children's Hospital, Nanchang, Jiangxi, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 120
- Registration Number
- NCT04969939
- Locations
- 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇺🇸Jacksonville Ctr For Clin Res, Jacksonville, Florida, United States
🇺🇸Endo Res Solutions Inc, Roswell, Georgia, United States
Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- Conditions
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 750
- Registration Number
- NCT04952779
- Locations
- 🇰🇷
Sahm Yook Medical Center, Seoul, Korea, Republic of
🇰🇷Daejeon Endo Internal Medicine Clinic, Daejeon, Korea, Republic of
🇰🇷Soonchunhyang University Hospital, Cheonan, Chungcheongnam-do, Korea, Republic of